Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $27.73, but opened at $22.80. Bicara Therapeutics shares last traded at $24.9350, with a volume of 316,476 shares traded.
Analysts Set New Price Targets
Several brokerages have recently commented on BCAX. Morgan Stanley upped their target price on Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Monday, July 6th. Guggenheim started coverage on Bicara Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $42.00 price objective on the stock. The Goldman Sachs Group raised their price objective on shares of Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Tuesday, May 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.27.
View Our Latest Research Report on BCAX
Bicara Therapeutics Stock Down 10.0%
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, meeting the consensus estimate of ($0.82). Equities research analysts expect that Bicara Therapeutics Inc. will post -3.42 EPS for the current year.
Insider Buying and Selling at Bicara Therapeutics
In other Bicara Therapeutics news, CEO Claire Mazumdar sold 10,000 shares of the company’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $28.42, for a total transaction of $284,200.00. Following the sale, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at approximately $10,292,359.84. This represents a 2.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 28,000 shares of the stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total transaction of $807,800.00. Following the completion of the sale, the chief financial officer owned 129,855 shares of the company’s stock, valued at approximately $3,746,316.75. This represents a 17.74% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 88,450 shares of company stock worth $2,366,675 over the last ninety days. 13.80% of the stock is currently owned by corporate insiders.
Institutional Trading of Bicara Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of BCAX. Candriam S.C.A. acquired a new stake in Bicara Therapeutics during the 1st quarter worth approximately $4,750,000. UBS Group AG increased its stake in shares of Bicara Therapeutics by 97.4% in the 4th quarter. UBS Group AG now owns 192,191 shares of the company’s stock valued at $3,235,000 after acquiring an additional 94,829 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Bicara Therapeutics by 26.2% in the first quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock valued at $66,350,000 after buying an additional 692,933 shares in the last quarter. Orbimed Advisors LLC boosted its position in shares of Bicara Therapeutics by 219.1% during the first quarter. Orbimed Advisors LLC now owns 667,300 shares of the company’s stock valued at $13,273,000 after buying an additional 458,200 shares during the last quarter. Finally, Siren L.L.C. grew its holdings in Bicara Therapeutics by 11.2% during the first quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock worth $115,421,000 after buying an additional 586,001 shares in the last quarter.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Featured Stories
- Five stocks we like better than Bicara Therapeutics
- Tesla’s Energy Business Just Got a SpaceX Demand Signal
- Oklo’s Revenue Transition Gives Bulls a New Reason to Watch
- Rocket Lab’s Record Quarter Still Left Investors Waiting on Neutron
- AMD’s Helios Launch Could Create Winners Beyond AMD Stock
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
